patent.fyi
Applications  /  US 2026/0355213
United States Patent Application Publication

US 2026/0355213 A1

Published
Nov 12, 2026
Filed
Dec 29, 2025
Earliest date on the face
Jun 28, 2023
Classification
A61K 31/55
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Longer repeat segment

What ifWhat if the segment indexed by n contains two repeat units?
Claim language“n is 0 or 1”

The structure sets n to 2 and retains the terminal attachment points of the indexed segment. The added repeat unit increases the number of backbone atoms along the path between those points.

1.3Hydrogen at both positions

What ifWhat if R1 and R2 are both hydrogen?
Claim language“at least one of R1 and R2 is said alkyl”

Hydrogen occupies each position and completes the valence at both attachment sites. The resulting structure has less substituent bulk at those sites than a structure with an alkyl group at either site.

1.6Oxygen linked substituent

What ifWhat if R25 is methoxy, with oxygen directly at the attachment point?
Claim language“selected from hydrogen, alkyl and cycloalkyl”

An oxygen atom links the scaffold to the methyl group. The oxygen provides a hydrogen-bond acceptor and changes the polarity at R25.

1.8Cyano at the ring position

What ifWhat if R34 is cyano and the other four positions are hydrogen?
Claim language“at least one of R32-R36, preferably at least one of R32, R34 and R36 is halo”

The nitrile carbon attaches directly at R34. The cyano group withdraws electron density and supplies a dipole without a halogen at any of the five positions.

1.10Alkenyl substituent at R37

What ifWhat if R37 is vinyl and R38 is hydrogen?
Claim language“selected from hydrogen alkyl and cycloalkyl”

The vinyl group attaches through one of its double-bonded carbon atoms. The carbon–carbon double bond holds the two carbons in a planar geometry and restricts rotation between them.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Formulation checks on a manufacturing line

A pharmaceutical manufacturing line uses the intracellular infection formulation as the test material during filling. An automated sampler diverts filled units from the beginning, middle and end of each run to a quality control station. Liquid chromatography measures active compound content, and a gravimetric station measures fill mass. The batch record links both measurements to the corresponding fill times.

Component substitution

Doxycycline as the active component

An oral pharmaceutical composition uses doxycycline in place of the formula-defined active compound for treatment of a susceptible intracellular bacterial infection. A capsule contains doxycycline hyclate and microcrystalline cellulose in a dissolvable shell. After the capsule dissolves, absorbed doxycycline enters host cells and inhibits bacterial protein synthesis by binding to the bacterial 30S ribosomal subunit.

Parameter or scale variation

Two volumes for dissolution testing

A paddle dissolution apparatus holds one oral dosage unit of the pharmaceutical composition per vessel. Separate runs use 500 mL and 900 mL of the same dissolution medium at 37 °C and a paddle speed of 50 revolutions per minute. Samples collected at 5, 15, 30 and 60 minutes pass through a filter before liquid chromatography. The measured concentrations and vessel volumes yield release profiles after correction for the active compound removed during sampling.

Combination with existing systems

Intracellular exposure in a perfused chip

A microfluidic cell culture chip integrates a dosing reservoir, a perfusion pump and a chamber lined with uninfected mammalian cells. The pump delivers culture medium containing the active compound through the chamber and directs the outlet into timed collection tubes. A terminal rinse removes residual medium before the cells are lysed. Liquid chromatography coupled with mass spectrometry measures the active compound in both the outlet fractions and cell lysate.

Formulation release across a dialysis membrane

A two-chamber dialysis apparatus pairs a donor chamber containing the pharmaceutical composition with a stirred receiver chamber containing buffer. A membrane separates the chambers and passes the dissolved active compound while retaining suspended formulation particles. A parallel donor chamber containing the active compound in solution measures the contribution of membrane transport to the observed release rate. Liquid chromatography measures the active compound in sequential receiver samples.

Automated or data-driven variant

Automated imaging of host cell tolerance

A liquid handler dispenses a concentration series of the active compound onto uninfected mammalian cells in a multiwell plate. The plate includes vehicle controls and cell-free wells for background measurement. An automated microscope images a nuclear stain and a membrane-impermeant viability dye in each well. Image analysis counts nuclei and calculates the fraction of dye-positive cells at each concentration after background correction.

Specific version of a part

Ethyl paired with hydrogen

R1 is ethyl and R2 is hydrogen. The ethyl group contains two carbons and attaches through its methylene carbon.

Fluoro and methoxy substitution

R3 is fluoro, R4 is methoxy, and R5 through R14 are hydrogen. Fluorine bonds directly at R3, and the methoxy group bonds through oxygen at R4.

Methyl and cyclopropyl pairing

R30 is methyl and R31 is cyclopropyl. The cyclopropyl group attaches through one carbon of its three-membered ring.

Hydroxy and trifluoromethyl substitution

R61 is hydroxy, R62 is trifluoromethyl, and R63 and R64 are hydrogen. The hydroxy group attaches through oxygen, and the trifluoromethyl group attaches through the carbon bearing three fluorine atoms.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,179,834 B2
Published
Feb 20, 2007
Filed
Jun 20, 2003
Class
A61K 31/407
Document BUS 2007/0219343 A1
Published
Sep 20, 2007
Filed
May 23, 2005
Class
C07D 265/22
Claim 1
Document A
Document B
1.1the pharmaceutical composition comprises at least one compound represented by Formula I, II, IV, V, VI or VII: wherein: n is 0 or 1
The compounds of the invention may be formulated into pharmaceutical compositions as natural or salt forms.
A · US 7,179,834 B2 · ¶ 48
1.2R1 and R2 are each independently selected from hydrogen and alkyl, preferably a lower alkyl of 1 to 4 carbon atoms in length
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
In a preferred aspect the invention relates to new isobenzoxazinones of formula (I) wherein R1 represents a long chain alkyl or isoalkyl substituent with CnH2n+1 and n=8-18, X represents —O— and R2, R3, R4 and R5 independently represent a substituent selected from hydrogen, fluorine, chlorine, bromine or C1-4 alkyl.
B · US 2007/0219343 A1 · ¶ 22
1.3wherein at least one of R1 and R2 is said alkyl
In a preferred aspect the invention relates to new isobenzoxazinones of formula (I) wherein R1 represents a long chain alkyl or isoalkyl substituent with CnH2n+1 and n=8-18, X represents —O— and R2, R3, R4 and R5 independently represent a substituent selected from hydrogen, fluorine, chlorine, bromine or C1-4 alkyl.
B · US 2007/0219343 A1 · ¶ 22
1.4R3-R14 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, thiol, thioalkoxy, amine, cyano and nitro
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
1.5R15-R24 are each independently selected from hydrogen, alkyl, cycloalkyl, amine, halo, hydroxy, thiol, alkoxy, and thioalkoxy
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
1.6R25 is selected from hydrogen, alkyl and cycloalkyl
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
1.7wherein: R30 and R31 are each independently selected from hydrogen, alkyl and cycloalkyl
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
1.8R32-R36 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, thiol, thioalkoxy, amine, cyano and nitro, provided that at least one of R32-R36, preferably at least one of R32, R34 and R36 is halo
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
1.9A is selected from: wherein the curved line represents an attachment point to NR30−
1.10R37 and R38 are each independently selected from hydrogen alkyl and cycloalkyl
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
1.11wherein: R61-R64 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, thioalkoxy
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11
1.12R65 and R66 are each independently selected from hydrogen, alkyl and cycloalkyl R67-R78 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol and thioalkoxy R80 represents one or more (1, 2, 3, 4 or 5) substituents on the phenyl ring, or is absent wherein each of these substituents, if present, is independently selected from alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, and thioalkoxy wherein: R80 and R81 are each independently selected from hydrogen, alkyl and cycloalkyl R82-R86 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, and thioalkoxy R87-R90 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, and thioalkoxy R91-R94 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, and thioalkoxy R95-R98 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, and thioalkoxy wherein: R100 is hydrogen, alkyl or cycloalkyl R101-R105 are each independently selected from hydrogen, alkyl, cycloalkyl, aryl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, thioalkoxy, heteroaryl, cyano, and nitro wherein at least one of R101-R105, preferably R101, is aryl R106-R109 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol and thioalkoxy R110-R113 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol and thioalkoxy, or, alternatively, two of R110-R113 form together a substituted or unsubstituted cyclic ring (alicyclic, heteroalicyclic, aryl or heteroaryl) R114-R117 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol and thioalkoxy wherein: X is O, S or NR120 R119 and R120 (if present) are each independently selected from hydrogen, alkyl or cycloalkyl R121-R125 are each independently selected from hydrogen, alkyl, cycloalkyl, aryl, halo, haloalkyl, amine, hydroxy, alkoxy, aryloxy, thioaryloxy, thiol, thioalkoxy, heteroaryl, cyano and nitro, or, alternatively or in addition, two of R121-R125 form together a substituted or unsubstituted cyclic ring (alicyclic, heteroalicyclic, aryl or heteroaryl) R126-R129 are each independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, amine, hydroxy, alkoxy, thiol, thioalkoxy, heteroalicyclic, heteroaryl, and aryloxy, provided that at least one of R121-R125 and at least one of R126-R129 is other than hydrogen.
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substit
A · US 7,179,834 B2 · ¶ 11

An empty cell means only that no passage was reproduced there.

Statements in these documents
Thus, there is a continuing need for anti-neoplastic agents that are effective in inhibiting the proliferation of hyperproliferative cells while also exhibiting IC50 values lower than those values found for current anti-neoplastic agents, thereby resulting in marked decrease in potentially serious side effects.
A · US 7,179,834 B2 · ¶ 8
The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.
A · US 7,179,834 B2 · ¶ 9
The present invention relates to new isobenzoxazinones, in particular of formula (I), and their use as ultraviolet light absorbers for organic materials, in particular for organic polymers.
B · US 2007/0219343 A1 · ¶ 1
UV absorbers help to prevent polymer degradation by reducing the harmful effects of ultraviolet rays by absorption through chromophores and by lowering the initiation rate through deactivation of excited states in the polymer matrix.
B · US 2007/0219343 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355213 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355213/, SHA-256 5fed1460f7de79c7edb1333521a4458fd21ad8348bbc5748c4c90b29630e18df
First published
Permanent addresshttps://patent.fyi/US20260355213/
Content fingerprint (SHA-256)5fed1460f7de79c7edb1333521a4458fd21ad8348bbc5748c4c90b29630e18df
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi